Melasma Melasma, Botulinum toxin, Pigment, Melanogenesis, UVA, Melanin, Tyrosinase
Conditions
Interventions
Intradermal botulinum toxin injection,0.9%normal saline injection intradermally
Experimental Drug,Placebo Comparator Drug
Botulinum toxin,Normal saline
Sponsors
None listed
Eligibility
Sex/Gender
Female
Age
20 Years to 55 Years
Inclusion criteria
Inclusion criteria: 1.aged 20-55 years 2.Fitzpatrick skin types III and IV 3.patients had not received any melasma treatments (such as topical agents or light-based treatments) for at least one month prior to participation 4.any botulinum toxin (BoNT) injections were withheld for at least six months before the study
Exclusion criteria
Exclusion criteria: 1.pregnancy 2.lactation 3.use of exogenous hormones 4.thyroid disease 5.allergy or resistance to BoNT 6.bleeding disorders 7.neuromuscular disorders 8.active infections or skin diseases
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Melasma Area and Severity Index score before, 2 wk, 1 mo, 2 mo, 3 mo Score,Physician global assessment score before, 2wk, 1mo, 2 mo, 3mo Score | — |
Secondary
| Measure | Time frame |
|---|---|
| Patient satisfaction 2wk, 1mo, 2mo, 3mo Score | — |
Countries
Thailand
Contacts
Public ContactWilai Thanasarnaksorn
Samitivej sukhumvit hospital
Outcome results
None listed